@article {Linden443作者={和Cardell林登,LO和俊井和纳达尔,JA}, title = {Bronchodilation由垂体腺苷酸cyclase-activating肽和相关肽},体积={14}={2},页面={443 - 451}={1999},出版商={欧洲呼吸学会},文摘={垂体腺苷酸cyclase-activating肽(PACAP)存在于神经附近的支气管和血管平滑肌的航空公司。188bet官网地址至少一个内生的PACAP形式,PACAP 1-27,高亲和力结合位点在肺部,可能包括胆碱能神经终端,支气管平滑肌,上皮细胞和单核炎症细胞。行动的机制PACAP 1-27和1-38体内包括内源性儿茶酚胺、肽酶和一氧化氮,根据组织类型。细胞,环腺苷酸(cAMP)以及钙和钠动员可能参与其中。PACAP 1-27 1-38抑制气管平滑肌的语气在体外和体内。的抑制作用PACAP 1-38比的持续PACAP 1-27,体外和体内。PACAP 1-38也引起更多的持续抑制支气管狭窄吸入体内后,比——血管活性肠肽(VIP)。PACAP 1-27静脉注射实际上废除allergen-induced体内支气管收缩。新颖的合成类似物PACAP 1-27导致更多持续抑制气道平滑肌的语气在体外和体内比PACAP 1-27或1-38。两个PACAP 1-27和1-38抑制动脉平滑肌的语气,但管理PACAP 1-27, 1-38或结构模拟PACAP 1-27航空,诱发没有心血管副作用剂量抑制支气管收缩。 PACAP 1-38 enhances phagocytosis in macrophages and inhibits the release of the pro-inflammatory cytokine interleukin-2 in lymphocytes, suggesting antiinflammatory effects. It is concluded that pituitary adenylate cyclase-activating peptide 1-27 and 1-38, or structurally related molecules, may be useful as bronchodilators but their effect on human bronchial smooth muscle and on human inflammatory cells is in need of evaluation.}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/14/2/443}, eprint = {//www.qdcxjkg.com/content/14/2/443.full.pdf}, journal = {European Respiratory Journal} }